Browse by tag

acquired-hemophilia

• How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• What is your approach to the use of porcine FVIII in acquired hemophilia A?

acquired-von-willebrand-syndrome

• What are the mechanisms of acquired von Willebrand syndrome?

adverse-effects

• Are pre-medications required for IV iron empirically in a patient with a history of anaphylaxis unrelated to the IV iron?
• Can you use TPO-RAs in patients with ITP and positive APLAs?
• Is IV iron safe to administer in acute infections?
• What is the mechanism of iron-induced hypophosphatemia?

anemia

• How do you treat severe anemia in individuals who cannot receive blood products?

anticoagulation

• Can persons with hemophilia receive antithrombotic therapy?
• In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?

assay-discrepancy

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• What is the influence of race and ethnicity on the diagnosis of VWD?
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

atrial-fibrillation

• In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?

b12-deficiency

• Where are iron and B12 absorbed in the GI tract?

bleeding

• Can emicizumab be used to treat patients with severe type 3 VWD?
• Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?
• How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• How do you diagnose bleeding disorders of unknown cause (BDUC)?
• How does congenital dysfibrinogenemia present in women?
• In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?
• What are the bleeding manifestations of vitamin C deficiency?
• What are the mechanisms of acquired von Willebrand syndrome?
• What data supports the use of sirolimus in refractory ITP?
• What is considered a safe threshold for neuraxial anesthesia in patients with bleeding disorders?
• What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• What is the difference between hemophilia carriers and hemophilia?
• What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?
• What treatment options are available for patients with FVII deficiency?

consultative-hematology-101

• How do you treat severe anemia in individuals who cannot receive blood products?
• Is IV iron safe to administer in acute infections?
• Outline an approach to neutropenia for acutely ill patients who present to hospital with a normal CBC.
• What are the bleeding manifestations of vitamin C deficiency?
• What are the recommendations for endoscopy in patients presenting with confirmed IDA?
• What are thrombotic microangiopathies?
• Where can I find a comprehensive review of sickle cell disease?

diagnosis

• Describe the natural history, definition, diagnosis, investigations, and management of patients with confirmed and suspected VWD.
• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• How do you diagnose bleeding disorders of unknown cause (BDUC)?
• Outline an approach to neutropenia for acutely ill patients who present to hospital with a normal CBC.
• Should we perform bone marrow biopsies in patients with ITP?
• What are the recommendations for endoscopy in patients presenting with confirmed IDA?
• What are thrombotic microangiopathies?
• What is PIMT (persistent isolated mild thrombocytopenia), and is it clinically significant?
• What is the influence of race and ethnicity on the diagnosis of VWD?
• What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?

doac

• In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?

factor-ix

• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

factor-replacement

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• What is your approach to the use of porcine FVIII in acquired hemophilia A?
• What treatment options are available for patients with FVII deficiency?

factor-vii

• What treatment options are available for patients with FVII deficiency?

factor-viii

• Can emicizumab be used to treat patients with severe type 3 VWD?
• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• What is the F8 gene duplication (FVIII Padua)?
• What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• What is your approach to the use of porcine FVIII in acquired hemophilia A?

gene-therapy

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

genetics

• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• What is the F8 gene duplication (FVIII Padua)?
• What is the difference between hemophilia carriers and hemophilia?

hemophilia-a

• Can persons with hemophilia receive antithrombotic therapy?
• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• What is the difference between hemophilia carriers and hemophilia?

hemophilia-b

• Can persons with hemophilia receive antithrombotic therapy?
• What is the difference between hemophilia carriers and hemophilia?
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

inhibitors

• Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• What is your approach to the use of porcine FVIII in acquired hemophilia A?

iron-deficiency

• Are pre-medications required for IV iron empirically in a patient with a history of anaphylaxis unrelated to the IV iron?
• Is IV iron safe to administer in acute infections?
• What are the recommendations for endoscopy in patients presenting with confirmed IDA?
• What is the mechanism of iron-induced hypophosphatemia?
• Where are iron and B12 absorbed in the GI tract?

iron-therapy

• Are pre-medications required for IV iron empirically in a patient with a history of anaphylaxis unrelated to the IV iron?
• How do you treat severe anemia in individuals who cannot receive blood products?
• Is IV iron safe to administer in acute infections?
• What is the mechanism of iron-induced hypophosphatemia?

itp

• Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?
• Can you use TPO-RAs in patients with ITP and positive APLAs?
• Is IVIG use in ITP associated with increased risk of thrombosis?
• Should we perform bone marrow biopsies in patients with ITP?
• What data supports the use of sirolimus in refractory ITP?
• What is PIMT (persistent isolated mild thrombocytopenia), and is it clinically significant?

ivig

• Is IVIG use in ITP associated with increased risk of thrombosis?

laboratory-assays

• Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• How do you diagnose bleeding disorders of unknown cause (BDUC)?
• What is the influence of race and ethnicity on the diagnosis of VWD?
• What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?
• Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?

neutropenia

• Outline an approach to neutropenia for acutely ill patients who present to hospital with a normal CBC.

platelet-disorders

• Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?
• Should we perform bone marrow biopsies in patients with ITP?
• What data supports the use of sirolimus in refractory ITP?
• What is PIMT (persistent isolated mild thrombocytopenia), and is it clinically significant?
• What is considered a safe threshold for neuraxial anesthesia in patients with bleeding disorders?
• What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?

rare-bleeding-disorders

• How does congenital dysfibrinogenemia present in women?
• What is considered a safe threshold for neuraxial anesthesia in patients with bleeding disorders?
• What treatment options are available for patients with FVII deficiency?

sickle-cell-disease

• Where can I find a comprehensive review of sickle cell disease?

thrombophilia

• Can you use TPO-RAs in patients with ITP and positive APLAs?
• Should patients with antiphospholipid antibody syndrome without thrombotic or obstetric complications receive aspirin for primary prophylaxis?
• What is the F8 gene duplication (FVIII Padua)?

thrombosis

• Can persons with hemophilia receive antithrombotic therapy?
• Can you use TPO-RAs in patients with ITP and positive APLAs?
• Is IVIG use in ITP associated with increased risk of thrombosis?
• Should patients with antiphospholipid antibody syndrome without thrombotic or obstetric complications receive aspirin for primary prophylaxis?

thrombotic-microangiopathy

• What are thrombotic microangiopathies?

venous-thromboembolism

• What is the F8 gene duplication (FVIII Padua)?

vitamin-c-deficiency

• What are the bleeding manifestations of vitamin C deficiency?

vwd

• Can emicizumab be used to treat patients with severe type 3 VWD?
• Describe the natural history, definition, diagnosis, investigations, and management of patients with confirmed and suspected VWD.
• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• What is the influence of race and ethnicity on the diagnosis of VWD?

vwf

• Describe the natural history, definition, diagnosis, investigations, and management of patients with confirmed and suspected VWD.
• How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• What are the mechanisms of acquired von Willebrand syndrome?
• What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• What is the influence of race and ethnicity on the diagnosis of VWD?